Treating to a Target in Established Active Rheumatoid Arthritis Patients Receiving a Tumor Necrosis Factor Inhibitor: Results From a Real‐World Cluster‐Randomized Adalimumab Trial

Treating to a Target in Established Active Rheumatoid Arthritis Patients Receiving a Tumor Necrosis Factor Inhibitor: Results From a Real‐World Cluster‐Randomized Adalimumab Trial

Objective In early rheumatoid arthritis (RA), treating to a target is more effective than routine care (RC). Our aim was to determine if treating to a target has better outcomes than RC in established active RA. Methods We used a real‐world, 18‐month cluster‐randomized trial in established active RA...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Arthritis care & research (2010) 2013-09, Vol.65 (9), p.1401-1409
Hauptverfasser: Pope, Janet E., Haraoui, Boulos, Rampakakis, Emmanouil, Psaradellis, Eliofotisti, Thorne, Carter, Sampalis, John S.
Format: Artikel
Sprache:eng
Schlagworte:
Adalimumab
Adult
Aged
Antibodies, Monoclonal, Humanized - administration & dosage
Antirheumatic Agents - administration & dosage
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - epidemiology
Cluster Analysis
Female
Humans
Male
Middle Aged
Molecular Targeted Therapy - methods
Single-Blind Method
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective In early rheumatoid arthritis (RA), treating to a target is more effective than routine care (RC). Our aim was to determine if treating to a target has better outcomes than RC in established active RA. Methods We used a real‐world, 18‐month cluster‐randomized trial in established active RA patients treated with adalimumab. Physicians were randomized to RC, treating to a Disease Activity Score in 28 joints (DAS28) of
ISSN:2151-464X
2151-4658
DOI:10.1002/acr.22010